Skip to main content

Table 2 Clinical outcomes of ATTAIN study patients with Staphylococcus aureus nosocomial pneumonia according to vancomycin trough levels

From: Effect of vancomycin serum trough levels on outcomes in patients with nosocomial pneumonia due to Staphylococcus aureus: a retrospective, post hoc, subgroup analysis of the Phase 3 ATTAIN studies

  Vancomycin trough level (μg/mL),
n/N (%)
p*
  < 10 10 to < 15 ≥ 15  
All patients     
  Clinical cure 21/30 (70) 18/33 (55) 17/35 (49) 0.09
   MRSA 13/20 (65) 15/26 (58) 16/30 (53) 0.42
   MRSA based on median trough levels collected up to study Day 4 14/26 (54) 11/20 (55) 8/16 (50) 0.83
  Any serious adverse event 4/30 (13) 8/33 (24) 13/35 (37) 0.03
  Renal adverse events 0/30 (0) 1/33 (3) 6/35 (17) <0.01
  Significant increases in serum creatinine 0/30 (0) 0/33 (0) 4/35 (11) 0.02
   Increase 2 to < 3 times from baseline 0/30 (0) 0/33 (0) 1/35 (3) --
   Increase ≥ 3 times from baseline 0/30 (0) 0/33 (0) 3/35 (9) --
  Deaths 3/30 (10) 5/33 (15) 7/35 (20) 0.31
  Median length of therapy in days (interquartile range) 10 (6, 12) 11 (8, 14) 11 (8, 15) 0.14¥
Excluding patients with ARF or vancomycin exposure within 7 days§     
  Clinical cure 12/17 (71) 9/15 (60) 3/11 (27) 0.04
  Any serious adverse event 2/17 (12) 3/15 (20) 6/11 (55) 0.02
  Renal adverse events 0/17 (0) 0/15 (0) 3/11 (27) 0.01
  Significant increases in serum creatinine 0/17 (0) 0/15 (0) 2/11 (18) 0.06
  Deaths 2/17 (12) 3/15 (20) 5/11 (45) 0.07
  1. ATTAIN, Assessment of Telavancin for Treatment of Hospital-Acquired Pneumonia; ARF, acute renal failure; MRSA, methicillin-resistant Staphylococcus aureus.
  2. *Two-sided p-value for Cochran-Armitage test for trend; p-value based on exact test reported for sparse data (any cell < 5).
  3. Renal failure, renal insufficiency, renal impairment, creatinine increased.
  4. ≥ 1.5 mg/dL and increase to at least 1.5× baseline.
  5. §Excluding patients with acute renal failure and/or vancomycin exposure within 7 days prior to the first dose of study medication.
  6. ¥Kruskall-Wallis.